ClinicalTrials.gg
RecruitingNCT06223633Updated Jun 10, 2026

PK(Pharmacokinetic) Papyrus Covered Coronary Stent System

An interventional study of PK Papyrus Covered Coronary Stent System in Coronary Disease, sponsored by Methodist Health System. Recruiting at 1 site in United States. Per ClinicalTrials.gov, last updated 2026-06-10.

Sponsored by Methodist Health System · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2023; still recruiting 3 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
41
Allocation
Not applicable
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 274 studies in Coronary Disease with a site in United States — 12 open to participants now, 23 under way, 2 of them phase 3. Coronary Disease · United States.

Planned enrollment
147th of 184
41 · median 200
Started
2023
with 2 others
No phase
78 of 274
6 open now
Primary completion
2027-08
later than 12 of 22 live
Registered
254th of 274
by date

Among the 274 studies in Coronary Disease with a site in United States, this one is the 147th largest by planned enrollment of the 184 interventional ones that give a count, is one of 3 that started in 2023, is one of 78 with no phase, reaches primary completion later than 12 of the 22 other live ones, and was the 254th registered.

Coronary Disease

1,522 studies on the registry are indexed under Coronary Disease; 167 are open to participants now.

Browse Coronary Disease studies →

Open to participants now

12 of the 274 studies in Coronary Disease with a site in United States are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 106 Coronary Disease studies recruiting now, 64 (60%) set no upper age limit and 19 (18%) stop at 75 or younger; 8 take children under 18; 10 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 274 studies in Coronary Disease with a site in United States, or all of them as a file.
02

Study summary

The PK Papyrus Covered Coronary Stent System is a coronary stent being used at Methodist Dallas Medical Center for patients with coronary perforations.

Read the detailed description

The FDA has approved the PK Papyrus Covered Coronary Stent System for use in patients being treated for acute perforations of native coronary arteries and coronary bypass grafts in vessels ranging from 2.5 to 5.0 mm in diameter, under a Humanitarian Device Exemption (HDE #H170004). Methodist Dallas Medical Center will use this device for treating the above-described patient population.

03

Conditions studied

  • Coronary Disease

Browse trials for

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with acute perforations of native coronary arteries and coronary bypass grafts in vessels 2.5 to 5.0 mm in diameter

Exclusion criteria

Exclusion Criteria:

  • Patients in whom antiplatelet agents or anticoagulation therapy is .
  • Patients with a known allergy or to amorphous silicon carbide or any other compound of the system (siloxane-based polyurethane, L-605 cobalt chromium alloy including tungsten and nickel).
  • Lesions that cannot be reached or treated with the system.
  • Lesions with threatened or abrupt closure during attempted pre-dilation prior to stent implantation.
  • Risk of treatment-related occlusion of vital coronary artery side branches.
  • Uncorrected bleeding disorders.
  • Allergy to contrast media.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
41 participants (estimated)

Study arms

  • Experimental
    PK Papyrus Covered Coronary Stent System

    PK Papyrus Covered Coronary Stent System has been approved for use in the treatment of free perforations, defined as free contrast extravasation into the pericardium, in native coronary vessels or saphenous vein bypass grafts greater than or equal to 2.75mm in diameter.

    Device: PK Papyrus Covered Coronary Stent System

Interventions

  • DevicePK Papyrus Covered Coronary Stent System

    PK Papyrus Covered Coronary Stent System has been approved for use in the treatment of free perforations, defined as free contrast extravasation into the pericardium, in native coronary vessels or saphenous vein bypass grafts greater than or equal to 2.75mm in diameter.

06

What researchers measure

Primary outcomes

  1. Determining the number of the unanticipated adverse events related to the use of PK Papyrus Coronary Stent Graft System

    Number of patients with PK Papyrus being treated for acute perforations of native coronary arteries and bypass grafts in vessels.

    Time frame: Up to 10 years

  2. Number of patients with the device

    number of patients with success coronary artery and bypass grafts

    Time frame: 10 years

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2023 (actual). Primary completion is estimated for Aug 2027, 48 months after the start.

Of 180 non-industry interventional studies with no phase under Coronary Disease, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 51. This study's planned 48 months is above that.

Counting every sponsor, half of 202 studies reached it within 25 months; a quarter within 14 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 4, 2020
First posted
Jan 25, 2024
StartActual
Aug 10, 2023
Primary completionEst.
Aug 2027
CompletionEst.
Aug 2028
Last update
Jun 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06223633
Responsible party
Sponsor
First posted
Jan 25, 2024
Start date
Aug 10, 2023
Primary completion
Aug 2027 (estimated)
Completion
Aug 2028 (estimated)
Last update
Jun 10, 2026

Study contacts

Colette Ngo Ndjom, M.S.
Contact
clinicalresearch@mhd.com
214-947-1279
Zaid Haddadin, M.S.
Contact
clinicalresearch@mhd.com
214-947-1280
Luis Bowen, M.D.
principal investigator · The Methodist Hospital Research Institute

Oversight

FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion